Dimethylformamide → HCID 54003210, compound
Reaction equation
Cl[C:2]1[C:11]2[C:6](=[CH:7][C:8]([O:14][CH2:15][CH:16]3[CH2:21][CH2:20][N:19](CC#N)[CH2:18][CH2:17]3)=[C:9]([O:12][CH3:13])[CH:10]=2)[N:5]=[CH:4][N:3]=1.[OH:25][C:26]1[CH:27]=[C:28]2[C:32](=[CH:33][CH:34]=1)[NH:31][CH:30]=[CH:29]2.[C:35](=O)([O-])[O-].[Cs+].[Cs+].C[N:42]([CH:44]=O)C>>[C:44]([CH2:35][CH:15]([CH:16]1[CH2:17][CH2:18][NH:19][CH2:20][CH2:21]1)[O:14][C:8]1[CH:7]=[C:6]2[C:11]([C:2]([O:25][C:26]3[CH:27]=[C:28]4[C:32](=[CH:33][CH:34]=3)[NH:31][CH:30]=[CH:29]4)=[N:3][CH:4]=[N:5]2)=[CH:10][C:9]=1[O:12][CH3:13])#[N:42]Participants
5
Conditions
- Temperature
- 90 °C
Procedure
A solution of 4-chloro-6-methoxy-7-((1-cyanomethylpiperidin-4-yl)methoxy)quinazoline (200 mg, 0.58 mmol) and 5-hydroxyindole (85 mg, 0.63 mmol) in DMF (3 ml) containing cesium carbonate (282 mg, 0.86 mmol) was stirred at 90° C. for 90 minutes. After cooling, the mixture was poured onto water (25 ml). The precipitate was filtered, dried under vacuum and purified by reverse phase column chromatography on silica (kromasil® C18) eluting with methanol/water (1% acetic acid) (1/1). The fractions containing the expected product were combined and evaporated to give 7-((1-cyanomethyl)piperidin-4-ylmethoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline (44 mg, 17%).
Workup
- temperatureAfter cooling
- additionthe mixture was poured onto water (25 ml)
- filtrationThe precipitate was filtered
- customdried under vacuum
- custompurified by reverse phase column chromatography on silica (kromasil® C18)
- washeluting with methanol/water (1% acetic acid) (1/1)
- additionThe fractions containing the expected product
- customevaporated
Sources & evidence
- ORD record
- ord-f444de9a91244262b159c3de8c35d021
- Source dataset
- uspto-grants-2006_07
- Patent number
- US07074800B1
Reaction notes
Loading…